CAR-T Cell Therapy Market Size and Forecast (2021

Description

List of Tables

According to our new research study on "CAR-T Cell Therapy Market Forecast to 2034 Global Analysis - by detector type, end users and geography," the market is anticipated to grow from US$ 4.48 billion in 2025 to US$ 19.31 billion by 2034, with a CAGR of 17.6% during 2026-2034. Personalized CAR-T cell therapy approaches are emerging as a high-growth category, with healthcare providers increasingly requiring patient-specific treatment strategies tailored to different hematological malignancies, target antigens, and lines of therapy, including B-cell lymphomas, leukemia, and multiple myeloma. Advances in cell engineering, antigen targeting, manufacturing technologies, and treatment personalization are supporting the development of next-generation CAR-T therapies with improved efficacy, safety, and broader patient applicability.

The growing burden of cancer, particularly hematological malignancies, remains a fundamental demand driver for CAR-T cell therapy. CAR-T has demonstrated its strongest clinical value in patients with aggressive or relapsed diseases for whom conventional chemotherapy, targeted medicines, transplantation, or antibody-based approaches may provide limited durable benefit. Published clinical evidence indicates that CAR-T therapies have achieved complete-remission rates of approximately 60-90% in selected relapsed/refractory B-cell leukemia, lymphoma, and multiple myeloma populations, illustrating the technology's ability to generate deep responses in difficult-to-treat patients.

The demand opportunity is particularly significant because lymphoma, leukemia, and multiple myeloma collectively represent a substantial population of patients requiring multiple lines of therapy. Disease relapse and treatment resistance continue to create a recurring need for innovative therapies, while improvements in cancer diagnosis and survival are increasing the number of patients living long enough to require subsequent treatment lines. CAR-T is also increasingly being positioned as a potentially definitive therapy rather than simply another sequential treatment, particularly where long-term remission can be achieved after a single infusion.

The market's growth is further supported by the expansion of manufacturing capacity and specialized treatment centers in North America, Europe, and Asia-Pacific. China has become particularly important, accounting for 1,006 of 1,908 CAR-T clinical trials identified globally in 2026 in one recent market analysis, highlighting the country's exceptionally active development ecosystem.

Increasing investment from pharmaceutical companies is also strengthening the pipeline and accelerating commercialization. Furthermore, growing healthcare expenditure in emerging markets such as China, India, Brazil, and the Middle East is creating opportunities to introduce lower-cost CAR-T products. The development of indigenous therapies is especially important because conventional CAR-T remains expensive and difficult to deliver in many countries.

Consequently, the combination of rising cancer prevalence, treatment resistance, expanding patient eligibility, and strong clinical efficacy is expected to sustain demand for CAR-T therapy globally.

The enterprises working in the CAR-T cell therapy Market have started Market consolidation efforts to a larger extent. More attention is being paid towards the enhancement of detection and imaging capabilities through full-field digital mammography, digital breast tomosynthesis, contrast-enhanced mammography, and image reconstruction innovations. For instance, in July 2026, Innovent Biologics, Inc. announced an exclusive license agreement for IBI355 (Spero R&D code: SP001), a third-generation Fc-silent anti-CD40L antibody. Spero will receive exclusive rights to develop, research, manufacture, and commercialize IBI355 worldwide, excluding Greater China, where Innovent retains rights. Spero currently expects to advance IBI355 into a Phase 2 study in IgG4-RD patients in Q2 2027; Innovent expects to initiate a Phase 2 trial in China for SjD by early 2027. Similarly, in June 2026, CARsgen Therapeutics Holdings Limited announced that as informed by the National Medical Products Administration (NMPA), the New Drug Application (NDA) of satricabtagene autoleucel (satri-cel), the proprietary autologous humanized Claudin18.2 CAR T-cell therapy product, was approved for the treatment of patients with Claudin18.2-positive, HER2-negative advanced gastric/ gastroesophageal junction adenocarcinoma (G/GEJA) who have failed at least two prior lines of therapy. Satri-cel is the world's first approved CAR T-cell therapy product for the treatment of solid tumors. The Market analysis and industry trends have been assessed with the help of publicly available information provided by the FDA, NCI, WHO, company annual reports, investor presentations, regulatory documents, official product documents, government publications, peer reviewed journals, industry associations and other publicly available health care and medical devices resources.

The players operating in the CAR-T cell therapy Market have adopted a strategy that involves technological innovations, product development, strategic alliances, and geographical expansion to improve their competitive position in line with the changing needs of cancer treatment providers. Much importance has been placed on advancements in CAR-T cell therapy technologies for applications such as lymphomas, leukemia, and multiple myeloma, leveraging innovations in cell engineering, target antigen selection, manufacturing processes, and next-generation CAR-T constructs. An analysis of the CAR-T cell therapy Market and industry trends was done through the use of publicly available data from the U.S. Food and Drug Administration (FDA), National Cancer Institute (NCI), World Health Organization (WHO), company annual reports, investor presentations, product literature, government publications, scientific publications, clinical trial registries, and other publicly available sources on oncology and cell and gene therapies.

Product Code: TIPRE00029935

1. Executive Summary

1.1 Analyst Market Outlook
1.2 Market Attractiveness

2. CAR-T Cell Therapy Market Landscape

2.1 Overview
2.2 Value Chain Analysis
- 2.2.1 Raw Material Suppliers / Components
- 2.2.2 Manufacturers / Process / Technology
- 2.2.3 Distribution Landscape
- 2.2.4 End User
- 2.2.5 Level of Integration
2.3 Supply Chain Analysis
- 2.3.1 List of Manufacturers/Suppliers
- 2.3.2 List of Potential Customers
2.4 Porter's Five Force Analysis
- 2.4.1 Bargaining Power of Suppliers: Moderate to High
- 2.4.2 Bargaining Power of Buyers: High
- 2.4.3 Threat of New Entrants: Moderate
- 2.4.4 Threat of Substitutes: Moderate
- 2.4.5 Competitive Rivalry: High
2.5 PEST Analysis
2.6 Impact of Artificial Intelligence (AI)
2.7 Product or Technology Roadmap
2.8 Sustainability and ESG Trends
- 2.8.1 Environmental Trends
- 2.8.2 Social Trends
- 2.8.3 Governance Trends
2.9 Regulatory Framework

3. Competitive Landscape

3.1 Company Benchmarking by Key Players
3.2 Market Share Analysis, 2025 - By Key Players
3.3 Market Concentration

4. CAR-T Cell Therapy Market - Key Industry Dynamics

4.1 Market Drivers
- 4.1.1 Expansion of CAR-T Therapy into Earlier Treatment Lines and New Indications
- 4.1.2 Increasing Cancer Burden and High Unmet Need in Hematological Malignancies
- 4.1.3 Advancement of Cell Engineering and Manufacturing Technologies
4.2 Market Restraints
- 4.2.1 High Treatment and Manufacturing Costs
- 4.2.2 Complex Manufacturing and Logistical Requirements
- 4.2.3 Treatment-Related Toxicity and Long-Term Safety Concerns
4.3 Market Opportunities
- 4.3.1 CAR-T Therapy for Solid Tumors
- 4.3.2 Expansion into Autoimmune Diseases
- 4.3.3 Emerging Markets and Lower-Cost CAR-T Manufacturing
4.4 Future Trends
- 4.4.1 Shift Toward Allogeneic and Off-the-Shelf CAR-T
- 4.4.2 Emergence of In-Vivo CAR-T Therapy
- 4.4.3 Development of Multi-Target and Next-Generation CAR Constructs
4.5 Impact of Drivers and Restraints

5. CAR-T Cell Therapy Market - Global Market Analysis

5.1 CAR-T Cell Therapy Market Revenue (US$ Million), 2021-2034
5.2 CAR-T Cell Therapy Market Forecast and Analysis

6. CAR-T Cell Therapy Market Revenue Analysis -Targeted Antigen

6.1 CAR-T Cell Therapy Market Forecasts and Analysis by Targeted Antigen
- 6.1.1 CD19
  - 6.1.1.1 Overview
  - 6.1.1.2 CD19: CAR-T Cell Therapy Market -Revenue, 2021-2034 (US$ Million)
- 6.1.2 BCMA
  - 6.1.2.1 Overview
  - 6.1.2.2 BCMA: CAR-T Cell Therapy Market -Revenue, 2021-2034 (US$ Million)

7. CAR-T Cell Therapy Market Revenue Analysis -Indication

7.1 CAR-T Cell Therapy Market Forecasts and Analysis by Indication
- 7.1.1 Lymphomas
  - 7.1.1.1 Overview
  - 7.1.1.2 Lymphomas: CAR-T Cell Therapy Market -Revenue, 2021-2034 (US$ Million)
- 7.1.2 Leukemia
  - 7.1.2.1 Overview
  - 7.1.2.2 Leukemia: CAR-T Cell Therapy Market -Revenue, 2021-2034 (US$ Million)
- 7.1.3 Multiple Myeloma
  - 7.1.3.1 Overview
  - 7.1.3.2 Multiple Myeloma: CAR-T Cell Therapy Market -Revenue, 2021-2034 (US$ Million)

8. CAR-T Cell Therapy Market Revenue Analysis -End User

8.1 CAR-T Cell Therapy Market Forecasts and Analysis by End User
- 8.1.1 Hospitals and Specialty Clinics
  - 8.1.1.1 Overview
  - 8.1.1.2 Hospitals and Specialty Clinics: CAR-T Cell Therapy Market -Revenue, 2021-2034 (US$ Million)
- 8.1.2 Ambulatory Surgical Centers
  - 8.1.2.1 Overview
  - 8.1.2.2 Ambulatory Surgical Centers: CAR-T Cell Therapy Market -Revenue, 2021-2034 (US$ Million)
- 8.1.3 Others
  - 8.1.3.1 Overview
  - 8.1.3.2 Others: CAR-T Cell Therapy Market -Revenue, 2021-2034 (US$ Million)

9. CAR-T Cell Therapy Market - Geographical Analysis

9.1 North America
- 9.1.1 North America CAR-T Cell Therapy Market Overview
- 9.1.2 North America: CAR-T Cell Therapy Market Revenue and Forecasts, 2021-2034 (US$ Million)
- 9.1.3 North America: CAR-T Cell Therapy Market- By Segmentation
  - 9.1.3.1 Targeted Antigen
  - 9.1.3.2 Indication
  - 9.1.3.3 End User
- 9.1.4 North America: CAR-T Cell Therapy Market Breakdown by Countries
  - 9.1.4.1 United States Market
    - 9.1.4.1.1 United States: CAR-T Cell Therapy Market Revenue and Forecasts, 2021-2034 (US$ Million)
    - 9.1.4.1.2 United States: CAR-T Cell Therapy Market- By Segmentation
      - 9.1.4.1.2.1 Targeted Antigen
      - 9.1.4.1.2.2 Indication
      - 9.1.4.1.2.3 End User
  - 9.1.4.2 Canada Market
    - 9.1.4.2.1 Canada: CAR-T Cell Therapy Market Revenue and Forecasts, 2021-2034 (US$ Million)
    - 9.1.4.2.2 Canada: CAR-T Cell Therapy Market- By Segmentation
      - 9.1.4.2.2.1 Targeted Antigen
      - 9.1.4.2.2.2 Indication
      - 9.1.4.2.2.3 End User
9.2 Europe
- 9.2.1 Europe CAR-T Cell Therapy Market Overview
- 9.2.2 Europe: CAR-T Cell Therapy Market Revenue and Forecasts, 2021-2034 (US$ Million)
- 9.2.3 Europe: CAR-T Cell Therapy Market- By Segmentation
  - 9.2.3.1 Targeted Antigen
  - 9.2.3.2 Indication
  - 9.2.3.3 End User
- 9.2.4 Europe: CAR-T Cell Therapy Market Breakdown by Countries
  - 9.2.4.1 United Kingdom Market
    - 9.2.4.1.1 United Kingdom: CAR-T Cell Therapy Market Revenue and Forecasts, 2021-2034 (US$ Million)
    - 9.2.4.1.2 United Kingdom: CAR-T Cell Therapy Market- By Segmentation
      - 9.2.4.1.2.1 Targeted Antigen
      - 9.2.4.1.2.2 Indication
      - 9.2.4.1.2.3 End User
  - 9.2.4.2 Germany Market
    - 9.2.4.2.1 Germany: CAR-T Cell Therapy Market Revenue and Forecasts, 2021-2034 (US$ Million)
    - 9.2.4.2.2 Germany: CAR-T Cell Therapy Market- By Segmentation
      - 9.2.4.2.2.1 Targeted Antigen
      - 9.2.4.2.2.2 Indication
      - 9.2.4.2.2.3 End User
  - 9.2.4.3 France Market
    - 9.2.4.3.1 France: CAR-T Cell Therapy Market Revenue and Forecasts, 2021-2034 (US$ Million)
    - 9.2.4.3.2 France: CAR-T Cell Therapy Market- By Segmentation
      - 9.2.4.3.2.1 Targeted Antigen
      - 9.2.4.3.2.2 Indication
      - 9.2.4.3.2.3 End User
  - 9.2.4.4 Italy Market
    - 9.2.4.4.1 Italy: CAR-T Cell Therapy Market Revenue and Forecasts, 2021-2034 (US$ Million)
    - 9.2.4.4.2 Italy: CAR-T Cell Therapy Market- By Segmentation
      - 9.2.4.4.2.1 Targeted Antigen
      - 9.2.4.4.2.2 Indication
      - 9.2.4.4.2.3 End User
  - 9.2.4.5 Spain Market
    - 9.2.4.5.1 Spain: CAR-T Cell Therapy Market Revenue and Forecasts, 2021-2034 (US$ Million)
    - 9.2.4.5.2 Spain: CAR-T Cell Therapy Market- By Segmentation
      - 9.2.4.5.2.1 Targeted Antigen
      - 9.2.4.5.2.2 Indication
      - 9.2.4.5.2.3 End User
  - 9.2.4.6 Rest of Europe Market
    - 9.2.4.6.1 Rest of Europe: CAR-T Cell Therapy Market Revenue and Forecasts, 2021-2034 (US$ Million)
    - 9.2.4.6.2 Rest of Europe: CAR-T Cell Therapy Market- By Segmentation
      - 9.2.4.6.2.1 Targeted Antigen
      - 9.2.4.6.2.2 Indication
      - 9.2.4.6.2.3 End User
9.3 Asia Pacific
- 9.3.1 Asia Pacific CAR-T Cell Therapy Market Overview
- 9.3.2 Asia Pacific: CAR-T Cell Therapy Market Revenue and Forecasts, 2021-2034 (US$ Million)
- 9.3.3 Asia Pacific: CAR-T Cell Therapy Market- By Segmentation
  - 9.3.3.1 Targeted Antigen
  - 9.3.3.2 Indication
  - 9.3.3.3 End User
- 9.3.4 Asia Pacific: CAR-T Cell Therapy Market Breakdown by Countries
  - 9.3.4.1 China Market
    - 9.3.4.1.1 China: CAR-T Cell Therapy Market Revenue and Forecasts, 2021-2034 (US$ Million)
    - 9.3.4.1.2 China: CAR-T Cell Therapy Market- By Segmentation
      - 9.3.4.1.2.1 Targeted Antigen
      - 9.3.4.1.2.2 Indication
      - 9.3.4.1.2.3 End User
  - 9.3.4.2 Japan Market
    - 9.3.4.2.1 Japan: CAR-T Cell Therapy Market Revenue and Forecasts, 2021-2034 (US$ Million)
    - 9.3.4.2.2 Japan: CAR-T Cell Therapy Market- By Segmentation
      - 9.3.4.2.2.1 Targeted Antigen
      - 9.3.4.2.2.2 Indication
      - 9.3.4.2.2.3 End User
  - 9.3.4.3 India Market
    - 9.3.4.3.1 India: CAR-T Cell Therapy Market Revenue and Forecasts, 2021-2034 (US$ Million)
    - 9.3.4.3.2 India: CAR-T Cell Therapy Market- By Segmentation
      - 9.3.4.3.2.1 Targeted Antigen
      - 9.3.4.3.2.2 Indication
      - 9.3.4.3.2.3 End User
  - 9.3.4.4 Australia Market
    - 9.3.4.4.1 Australia: CAR-T Cell Therapy Market Revenue and Forecasts, 2021-2034 (US$ Million)
    - 9.3.4.4.2 Australia: CAR-T Cell Therapy Market- By Segmentation
      - 9.3.4.4.2.1 Targeted Antigen
      - 9.3.4.4.2.2 Indication
      - 9.3.4.4.2.3 End User
  - 9.3.4.5 South Korea Market
    - 9.3.4.5.1 South Korea: CAR-T Cell Therapy Market Revenue and Forecasts, 2021-2034 (US$ Million)
    - 9.3.4.5.2 South Korea: CAR-T Cell Therapy Market- By Segmentation
      - 9.3.4.5.2.1 Targeted Antigen
      - 9.3.4.5.2.2 Indication
      - 9.3.4.5.2.3 End User
  - 9.3.4.6 Rest of APAC Market
    - 9.3.4.6.1 Rest of APAC: CAR-T Cell Therapy Market Revenue and Forecasts, 2021-2034 (US$ Million)
    - 9.3.4.6.2 Rest of APAC: CAR-T Cell Therapy Market- By Segmentation
      - 9.3.4.6.2.1 Targeted Antigen
      - 9.3.4.6.2.2 Indication
      - 9.3.4.6.2.3 End User
9.4 Rest of World
- 9.4.1 Rest of World CAR-T Cell Therapy Market Overview
- 9.4.2 Rest of World: CAR-T Cell Therapy Market Revenue and Forecasts, 2021-2034 (US$ Million)
- 9.4.3 Rest of World: CAR-T Cell Therapy Market- By Segmentation
  - 9.4.3.1 Targeted Antigen
  - 9.4.3.2 Indication
  - 9.4.3.3 End User

10. CAR-T Cell Therapy Market Industry Landscape

11. CAR-T Cell Therapy Market - Key Company Profiles

11.1 Bristol-Myers Squibb Co
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 Novartis AG
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 Gilead Sciences Inc
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 Johnson & Johnson
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
11.5 JW (Cayman) Therapeutics Co Ltd
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 Innovent Biologics Inc
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
11.7 Autolus Therapeutics Plc
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments
11.8 Shanghai Fosun Pharmaceutical Co Ltd
- 11.8.1 Key Facts
- 11.8.2 Business Description
- 11.8.3 Products and Services
- 11.8.4 Financial Overview
- 11.8.5 SWOT Analysis
- 11.8.6 Key Developments
11.9 Immunoadoptive Cell Therapy Private Limited
- 11.9.1 Key Facts
- 11.9.2 Business Description
- 11.9.3 Products and Services
- 11.9.4 Financial Overview
- 11.9.5 SWOT Analysis
- 11.9.6 Key Developments
11.10 CARsgen Therapeutics Holdings Limited
- 11.10.1 Key Facts
- 11.10.2 Business Description
- 11.10.3 Products and Services
- 11.10.4 Financial Overview
- 11.10.5 SWOT Analysis
- 11.10.6 Key Developments

12. Appendix

12.1 Glossary
12.2 Research Methodology and Approach
- 12.2.1 Secondary Research
- 12.2.2 Primary Research
- 12.2.3 Market Estimation Approach
  - 12.2.3.1 Supply Side Analysis
  - 12.2.3.2 Demand Side Analysis
- 12.2.4 Research Assumptions and Limitations
- 12.2.5 Currency Conversion
12.3 About The Insight Partners
12.4 Market Intelligence Cloud